Description: Orgenesis Inc. is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company's subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. The CTB activity is based on its technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into pancreatic beta cell-like insulin producing cells for patients with Type I Diabetes. It intends to advance a product that combines cell-based therapy and regenerative medicine, Autologous Insulin Producing (AIP) cells, into clinical development.
Home Page: www.orgenesis.com
ORGS Technical Analysis
20271 Goldenrod Lane
Germantown,
MD
20876
United States
Phone:
480 659 6404
Officers
Name | Title |
---|---|
Ms. Vered Caplan M.Sc. | Chairperson of the Board, CEO & Pres |
Mr. Neil T. Reithinger CPA | CFO, Sec. & Treasurer |
Dr. Efrat Assa Kunik | Chief Devel. Officer |
Prof. Sarah Ferber Ph.D. | Founder & Chief Scientific Officer |
Mr. Evan Fishman | Chief Financial Officer |
Dan Slonim | COO & GM of Orgenesis Israel |
Dr. Shimon Hassin Ph.D. | Chief Technology Officer |
Ms. Osher Partok Rheinisch | Gen. Counsel & Compliance Officer |
Mr. Vincent Vandamme | Sr. VP of Quality Strategy |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 1.6996 |
Price-to-Sales TTM: | 1.779 |
IPO Date: | 2012-03-12 |
Fiscal Year End: | November |
Full Time Employees: | 151 |